Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(1-isopropylpiperidin‑4‑yl)‑1‑(3‑methoxybenzyl)‑1H‑indole‑2‑carboxamide is a synthetic small molecule compound with the molecular formula C25H31N3O2 and a molecular weight of approximately 405.5 g/mol[2][9][3]. It is primarily referenced in chemical and pharmacological databases as an experimental or research compound, not as an approved pharmaceutical agent. The compound has been studied for its binding affinity to coagulation factor X, with reported Ki values in the nanomolar range, suggesting it may act as an inhibitor of this serine protease involved in the blood coagulation cascade[5][2][3]. No clinical development or therapeutic indication has been established for this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(1-isopropylpiperidin-4-yl)-1-(3-methoxybenzyl)-1H-indole-2-carboxamide.